Literature DB >> 30530802

Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.

Marco Picardi1, Roberta Della Pepa2, Claudia Giordano2, Irene Zacheo2, Novella Pugliese2, Chiara Mortaruolo2, Fabio Trastulli2, Antonio Giordano2, Mariano Lucignano2, Maria Di Perna2, Marta Raimondo2, Claudia Salvatore3, Fabrizio Pane2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30530802      PMCID： PMC6405330          DOI： 10.1182/blood-2018-10-878892

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  18 in total

1.  Using numerical results from systematic reviews in clinical practice.

Authors:  H J McQuay; R A Moore
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

Authors:  Charles F Eisenbeis; Michael A Caligiuri; John C Byrd
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

3.  Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.

Authors:  H-R Li; J-J Huang; H-Q Guo; X Zhang; Y Xie; H-L Zhu; L-Z Zhai; X-X Pu; Y Huang; C-C Guo; T-Y Lin
Journal:  J Viral Hepat       Date:  2010-11-05       Impact factor: 3.728

Review 4.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

5.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

6.  Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.

Authors:  Fei W Chen; Luke Coyle; Brett E Jones; Venessa Pattullo
Journal:  Liver Int       Date:  2013-03-24       Impact factor: 5.828

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.

Authors:  Marco Picardi; Fabrizio Pane; Concetta Quintarelli; Amalia De Renzo; Annalisa Del Giudice; Bianca De Divitiis; Marcello Persico; Rosanna Ciancia; Francesco Salvatore; Bruno Rotoli
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

9.  Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

Authors:  Seok Jin Kim; Chiun Hsu; Yu-Qin Song; Kevin Tay; Xiao-Nan Hong; Junning Cao; Jin Seok Kim; Hyeon Seok Eom; Joon Hyeok Lee; Jun Zhu; Kian-Meng Chang; Arry Harryanto Reksodiputro; Daryl Tan; Yeow Tee Goh; Jejung Lee; Tanin Intragumtornchai; Wee-Joo Chng; Ann-Lii Cheng; Soon Thye Lim; Cheolwon Suh; Yok-Lam Kwong; Won Seog Kim
Journal:  Eur J Cancer       Date:  2013-08-01       Impact factor: 9.162

Review 10.  Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.

Authors:  Min-Yue Zhang; Gui-Qi Zhu; Ke-Qing Shi; Ji-Na Zheng; Zhang Cheng; Zhuo-Lin Zou; Hong-Hui Huang; Fang-Yuan Chen; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-05-24
View more
  6 in total

1.  Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era".

Authors:  Marco Picardi; Claudia Giordano; Roberta Della Pepa; Novella Pugliese; Aldo Leone; Giuseppe Delle Cave; Rossella Iula; Fabrizio Pane; Giuseppe Gentile
Journal:  Oncologist       Date:  2021-02-24

2.  Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.

Authors:  Bilal Toka; Aydin Seref Koksal; Ahmet Tarik Eminler; Mukaddes Tozlu; Mustafa Ihsan Uslan; Erkan Parlak
Journal:  Dig Dis Sci       Date:  2020-07-29       Impact factor: 3.199

3.  Correspondence in reference to the previously published Epub manuscript: "Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677".

Authors:  Marco Picardi; Claudia Giordano; Roberta Della Pepa; Novella Pugliese; Aldo Leone; Giuseppe Gentile; Fabrizio Pane
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

4.  Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.

Authors:  Yung-Rung Lai; Ya-Lan Chang; Chiu-Hsiang Lee; Tung-Han Tsai; Kuang-Hua Huang; Chien-Ying Lee
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

Review 5.  Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.

Authors:  Yutaka Tsukune; Makoto Sasaki; Norio Komatsu
Journal:  Cancers (Basel)       Date:  2019-11-19       Impact factor: 6.639

Review 6.  Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators.

Authors:  Elaheh Kordzadeh-Kermani; Hossein Khalili; Iman Karimzadeh; Mohammadreza Salehi
Journal:  Infect Drug Resist       Date:  2020-02-18       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.